Cognito Therapeutics logo

Cognito Therapeutics, Inc.


Cognito Therapeutics Stock

Cognito Therapeutics is a pioneering medical technology company focused on developing innovative therapies for neurodegenerative diseases, particularly Alzheimer’s disease. Utilizing non-invasive neuromodulation techniques, Cognito Therapeutics seeks to improve cognitive and functional abilities in individuals suffering from neurological disorders. The company is known for its groundbreaking approach that leverages gamma wave stimulation to target and potentially mitigate the symptoms associated with Alzheimer’s.

Cognito Therapeutics Company Overview

Founded by leading neuroscientists, Cognito Therapeutics has positioned itself at the forefront of Alzheimer’s research through its development of a non-invasive therapy designed to stimulate brain activity. Under the leadership of CEO Brent Vaughan, a seasoned entrepreneur with a robust background in digital therapeutics and medical devices, the company has made significant strides in clinical development and therapeutic innovation​. Cognito’s core treatment involves a wearable device that administers visual and auditory stimulation to evoke gamma wave activity in the brain, a process critical for learning and memory. Research has shown that this treatment not only preserves cognitive functions but also reduces brain atrophy, a common feature in Alzheimer’s patients​. The therapeutic approach has been recognized with the FDA’s Breakthrough Device Designation, underscoring its potential as a significant advancement in the treatment of neurodegenerative diseases​. The company’s research efforts are bolstered by a dedicated team of experts. Chief Medical Officer Ralph Kern brings extensive neurology expertise, having previously held leadership roles at prominent biotechnology firms and academic institutions. Chief Scientific Officer Mihály Hajós is notable for his research in neuronal activity and its applications in treating Alzheimer’s disease, overseeing both preclinical and translational medicine efforts at Cognito​. Clinical trials, including the Phase 2 OVERTURE trial, have demonstrated promising results. Patients treated with Cognito’s technology showed a significant slowing of disease progression, marked by preserved cognition and daily function, and reduced brain volume loss. These studies underline the therapy's efficacy and safety, fostering hope for its wider application in the treatment of Alzheimer’s and potentially other neurodegenerative conditions. Cognito Therapeutics operates out of Cambridge, MA, and actively engages in expanding its research scope to explore further applications of its technology across multiple neurodegenerative diseases, aiming to improve the quality of life for patients worldwide​.

Management Team

Edward Boyden Co-Founder
Li-Huei Tsai Co-Founder
Brent Vaughan CEO
Ralph Kern Chief Medical Officer
Mihály Hajós Chief Scientific Officer
Christian Howell Chief Commercial Officer
Greg Weaver CFO
Kim Kwan CTO

Funding Information